Home »
RECENT NEWS

Visit the WFH News page to find out more about the events and developments that are making a difference today.

GF-2023-header

13th WFH Global Forum covers latest advances in bleeding disorders treatments and technologies

The 13th World Federation of Hemophilia (WFH) Global Forum was held in Montreal, Canada, on November 17 and 18, 2023, and brought healthcare professionals, patient advocates, government officials, and industry members from around the world together. The gathering covered the very latest scientific developments and challenges related to the treatment of bleeding disorders. This year, the WFH Global Forum and the Gene Therapy Round Table were merged into one event. By integrating the two topics, attendees had the chance to hear from a wider spectrum of leading experts in the field of inherited bleeding disorders in one place, in-person.

Also available in: Français Español

Day 1 of the WFH Global Forum focused on confronting the limitations of therapy, from plasma to gene therapy, and discussing treatment for people with mild or moderate hemophilia, women and girls with bleeding disorders, and people with rare bleeding disorders. Talks on inequities in healthcare delivery globally and innovative access programs were also given.

Day 2 started with an inspiring keynote presentation by Andre Picard, award-winning health and public policy journalist. Picard emphasized the importance of remembering and learning from the past as we enter a new era of bleeding disorders treatments. The next sessions focused on different WFH programs, access to gene therapy globally, and new treatments and technologies in the pipeline.

The 13th Global Forum provided a unique opportunity for participants to come together and collectively reassess various therapeutic options—both established and new—and discuss challenges and opportunities for better care and treatment. To find out more about the 13th WFH Global Forum, please click here.

The 13th edition of the WFH Global Forum is supported by funding from BioMarin, CSL Behring, Pfizer, Sobi and Spark Therapeutics.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?